DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced the publication of data from a single center, real-world study with one-year clinical follow-up of patients selected from the ...
A study has found that restorative neurostimulation continues to be effective in treating low-back pain caused by multifidus dysfunction after three years. This type of dysfunction occurs when the ...
Mainstay Medical Holdings plc has won U.S. FDA approval for its Reactiv8 implantable neurostimulation device. The company is eyeing a commercial launch of the system in early 2021. The FDA approved ...
DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced that the International Society for the Advancement of Spine Surgery (ISASS) has published a Statement on Restorative ...
The US Food and Drug Administration (FDA) has approved an implantable neurostimulation system (ReActiv8, Mainstay Medical) to treat intractable chronic low back pain associated with multifidus muscle ...
Mainstay Medical Holdings plc has won U.S. FDA approval for its Reactiv8 implantable neurostimulation device. The company is eyeing a commercial launch of the system in early 2021. The FDA approved ...
Low back pain is the biggest musculoskeletal issue affecting the world today. At any given moment, up to 33 percent of the population is dealing with low back pain. It is one of the most common ...
The Food and Drug Administration (FDA) has approved ReActiv8® (Mainstay Medical), an implantable neurostimulation system, for the treatment of intractable chronic low back pain. Specifically, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results